Skye Bioscience Inc. (SKYE)
SKYE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | SKYE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001516551 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued." | 10-Q 2026-11-13 |
| Cash and burn | $8.1M cash; operating cash flow -$9.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | 4,423,469 (2026-11-10); 32,057,461 a year earlier; 12,338,910 three years earlier. 1y figure adjusted for splits (1-for-8 overall); 3y figure adjusted for splits (1-for-8 overall). | Cover page 2026-11-10 |
| Reverse splits, 3 years | 1; latest 1-for-8 on 2026-08-24 | Source 2026-08-24 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 3 (8-K item 3.01) | 8-K 2026-08-19 |
| Auditor | CBIZ CPAs P.C., Morristown, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-06-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $445K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$10.8M | -$7.1M | $8.1M | $143K | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$12.5M | -$8.6M | $8.1M | $250K | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$14.4M | -$9.8M | $5.9M | $0 | Needs four quarters | 10-K 2026-03-10 |
| Q3 2025 2025-09-30 | Not filed | -$12.8M | -$13.4M | $18.4M | No debt tags | Needs four quarters | 10-Q 2025-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$17.6M | -$10.7M | $23.8M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$11.1M | -$9.2M | $46.4M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$9.7M | -$8.2M | $68.4M | $0 | Needs four quarters | 10-K 2026-03-10 |
| Q3 2024 2024-09-30 | Not filed | -$3.9M | -$5.3M | $67.4M | $0 | Needs four quarters | 10-Q 2025-11-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2024-05-17 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-11-12 |
Source: SEC EDGAR submissions feed, 634 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +10.1% |
| 1 month | -28.8% |
| 3 months | -74.8% |
| Year to date | -81.8% |
| 1 year | -90.1% |
| From 52-week high | -90.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CANF | Can-Fite Biopharma Ltd | $1.56 | +9.86% | $4.7M |
| PCSA | Processa Pharmaceuticals Inc. | $1.72 | -7.53% | $4.8M |
| PULM | Pulmatrix Inc. | $1.33 | +2.31% | $4.9M |
| SCNX | Scienture Holdings Inc. | $2.99 | +3.10% | $4.9M |
| CVKD | Cadrenal Therapeutics Inc. | $1.40 | -7.28% | $5.0M |
| NCNA | NuCana plc American Depositary Share | $0.8631 | -7.46% | $4.4M |
| CNSP | CNS Pharmaceuticals Inc. | $3.48 | +20.42% | $5.1M |
| KPRX | Kiora Pharmaceuticals Inc. | $0.9820 | -20.16% | $4.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier